Shenzhen Kangtai Biologica (300601.SZ)
Current Trading Session
Trading session ended at 01:10 PM Central Europe on Wednesday 21 March 2026.
The share price moved 0 % over the 24‑hour period.
Current trading price: CNY 12.49 on major exchanges.
Market capitalisation: CNY 13.8 bn.
Outstanding shares: 1.1 bn.
24‑hour trading volume: CNY 126.7 mn.
Share price change since the end of last month: ‑4.7 %.
Technical Indicators
200‑day simple moving average: CNY 12.36.
52‑week high: CNY 17.76 (11 November 2025).
52‑week low: CNY 10.7 (29 June 2026).
Dividend Announcement
Shenzhen Kangtai Biologica has approved a semi‑annual dividend for 2026.
- Dividend amount: 0.27 yuan in cash per ten shares.
- Record date: 27 October 2026.
- Payment date: 28 October 2026.
- Eligibility: All shareholders registered with the Shenzhen branch of the China Securities Depository and Clearing Company as of the record date.
- Distribution method:
- Standard shareholders receive the dividend through the clearing house.
- A limited number of individual shareholders receive the payment directly from the company.
- No share‑based compensation or capital‑contribution adjustments are attached to the dividend.
The dividend was approved during the special shareholders’ meeting held on 8 September 2026 and will be paid within two months.
Related Stock Performance (Last 24 Hours)
| Stock | Ticker | 24‑hour change | Current price | Market cap | P/E |
|---|---|---|---|---|---|
| Huadian Liaoning Energy De | 600396.SS | 0 % | CNY 11.21 | CNY 16.5 bn | 340.99 |
| Zhejiang Hisun Pharmaceutic | 600267.SS | 0 % | CNY 14.00 | CNY 16.5 bn | 17.82 |
| Xd | 2400.HK | +0.79 % | HKD 38.88 | HKD 19.3 bn | 11.09 |
| Qingdao East Steel Tower | 002545.SZ | 0 % | CNY 12.94 | CNY 16.5 bn | 9.64 |
| Sinochem | 600500.SS | 0 % | CNY 4.61 | CNY 16.5 bn | – |
Zhejiang Hisun Pharmaceutic Highlights
- Positive quarterly outlook with increasing sales of core drug products.
- Expanded supply‑chain reach and uptake of new therapeutic indications.
- Improved revenue and operating margins.
- Commercialisation strategy delivering higher cash flows.
- Analysts view the company’s profit dynamics as evidence that the broader innovation‑drug sector is fulfilling earlier R&D investments.
- Domestic innovation‑drug market experiencing a surge in international licensing deals, supporting the company’s performance.
Company Overview
Shenzhen Kangi Biological Products Co., Ltd. is a biotechnology firm headquartered in Shenzhen, China. The company focuses on the development, production, and sale of human vaccines, including:
- Cell‑free whitebait type b haemophilus combined vaccine
- Measles–rubella combined vaccine with live attenuated strain
- Haemophilus influenzae type b conjugate vaccine
- Recombinant hepatitis B vaccine
- Conventional hepatitis B vaccine
The company continues to expand its product portfolio and maintain its presence in the global vaccine market.